Compare Biocon with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs DISHMAN PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON DISHMAN PHARMA BIOCON /
DISHMAN PHARMA
 
P/E (TTM) x 34.4 25.1 137.0% View Chart
P/BV x 4.4 3.3 130.2% View Chart
Dividend Yield % 0.2 0.7 34.0%  

Financials

 BIOCON    DISHMAN PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
DISHMAN PHARMA
Mar-16
BIOCON /
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs707374 188.9%   
Low Rs554129 429.6%   
Sales per share (Unadj.) Rs91.9197.8 46.5%  
Earnings per share (Unadj.) Rs16.721.2 78.8%  
Cash flow per share (Unadj.) Rs24.234.7 69.6%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.20.8 20.0%  
Book value per share (Unadj.) Rs101.6179.9 56.5%  
Shares outstanding (eoy) m600.0080.69 743.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.91.3 539.3%   
Avg P/E ratio x37.711.9 318.0%  
P/CF ratio (eoy) x26.17.2 359.9%  
Price / Book Value ratio x6.21.4 443.5%  
Dividend payout %6.09.4 63.5%   
Avg Mkt Cap Rs m378,33020,306 1,863.2%   
No. of employees `0006.10.8 739.6%   
Total wages/salary Rs m11,6535,355 217.6%   
Avg. sales/employee Rs Th8,994.319,252.7 46.7%   
Avg. wages/employee Rs Th1,900.76,459.5 29.4%   
Avg. net profit/employee Rs Th1,635.32,064.1 79.2%   
INCOME DATA
Net Sales Rs m55,14415,961 345.5%  
Other income Rs m1,444265 544.1%   
Total revenues Rs m56,58816,226 348.8%   
Gross profit Rs m15,8834,103 387.1%  
Depreciation Rs m4,4781,091 410.6%   
Interest Rs m709944 75.1%   
Profit before tax Rs m12,1402,334 520.2%   
Minority Interest Rs m90-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,123624 340.4%   
Profit after tax Rs m10,0261,711 585.9%  
Gross profit margin %28.825.7 112.0%  
Effective tax rate %17.526.7 65.4%   
Net profit margin %18.210.7 169.6%  
BALANCE SHEET DATA
Current assets Rs m48,22811,018 437.7%   
Current liabilities Rs m30,3769,517 319.2%   
Net working cap to sales %32.49.4 344.3%  
Current ratio x1.61.2 137.1%  
Inventory Days Days68110 61.8%  
Debtors Days Days8635 245.4%  
Net fixed assets Rs m64,13016,304 393.3%   
Share capital Rs m3,000161 1,858.7%   
"Free" reserves Rs m57,98012,907 449.2%   
Net worth Rs m60,98014,516 420.1%   
Long term debt Rs m15,7664,189 376.3%   
Total assets Rs m121,92429,805 409.1%  
Interest coverage x18.13.5 522.1%   
Debt to equity ratio x0.30.3 89.6%  
Sales to assets ratio x0.50.5 84.5%   
Return on assets %8.88.9 98.8%  
Return on equity %16.411.8 139.5%  
Return on capital %16.817.5 95.6%  
Exports to sales %28.124.8 113.4%   
Imports to sales %18.93.7 504.7%   
Exports (fob) Rs m15,5063,956 391.9%   
Imports (cif) Rs m10,399596 1,743.9%   
Fx inflow Rs m15,5064,952 313.2%   
Fx outflow Rs m10,399697 1,492.4%   
Net fx Rs m5,1074,255 120.0%   
CASH FLOW
From Operations Rs m11,5462,786 414.4%  
From Investments Rs m-7,138-1,529 466.9%  
From Financial Activity Rs m-2,417-941 256.8%  
Net Cashflow Rs m2,103316 664.7%  

Share Holding

Indian Promoters % 40.4 61.4 65.8%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 3.7 227.0%  
FIIs % 10.7 12.7 84.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 22.1 90.0%  
Shareholders   109,995 46,261 237.8%  
Pledged promoter(s) holding % 0.0 35.8 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   FRESENIUS KABI ONCO.  ELDER PHARMA  SUVEN LIFE SCIENCES  ALKEM LABORATORIES  WOCKHARDT  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls Over 750 Points from Day's High; Metal and Realty Stocks Witness Selling(Closing)

After opening the day on a strong note, Indian share markets witnessed a sharp sell-off during closing hours today and ended lower.

Related Views on News

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 21, 2021 03:30 PM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS